|
|
Volumn 13, Issue 2, 2012, Pages 127-128
|
|
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE;
4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE;
ANTINEOPLASTIC AGENT;
DASATINIB;
IMATINIB;
PIPERAZINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PYRIMIDINE DERIVATIVE;
THIAZOLE DERIVATIVE;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL (TOPIC);
DRUG RESISTANCE;
HEALTH CARE DELIVERY;
HUMAN;
NOTE;
ORGANIZATION AND MANAGEMENT;
PRACTICE GUIDELINE;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS AS TOPIC;
DELIVERY OF HEALTH CARE;
DRUG RESISTANCE, NEOPLASM;
GREAT BRITAIN;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
PIPERAZINES;
PRACTICE GUIDELINES AS TOPIC;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
THIAZOLES;
MLCS;
MLOWN;
|
|
EID: 84858412616
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(12)70008-6 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
